12th August 2026
11th August 2026
K2 Therapeutics Appoints Dr. Ying Huang as Chief Executive Officer and Announces $50 Million Seed Financing
21st July 2026
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
16th July 2026
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400
15th June 2026
Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO
8th June 2026
Johnson & Johnson to Acquire Firefly Bio, Inc.
6th June 2026
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
21st May 2026
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
20th May 2026
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
19th May 2026